June 2006
Worldwide Biotech;Jun2006, Vol. 18 Issue 6, p5
Trade Publication
Focuses on the services agreement established between Strategic Diagnostics Inc. (SDI) and Berlex Inc. Move by Berlex to extend its services agreement to include newly commercialized Genomic Antibodies offering of SDI; Plan by SDI to provide polyclonal and monoclonal Genomic Antibodiesâ„¢ to Berlex; Information about Genomic Antibodiesâ„¢.


Related Articles

  • Magic bullets hit the target. Gura, Trisha // Nature;6/6/2002, Vol. 417 Issue 6889, p584 

    Explores pharmaceutical firms' efforts to develop monoclonal antibodies for used as drugs in the U.S. Clinical trials of monoclonal antibodies; Monoclonal therapies approved by the Food and Drug Administration; Effectiveness of monoclonals against cancer.

  • Feeding the pipeline with monoclonal antibodies. Papanikolaw, Jim // Chemical Market Reporter;11/23/98, Vol. 254 Issue 21, pFR15 

    Focuses on the market potential for monoclonal antibodies in the pharmaceuticals market. Mabs as the industry segment with the most number of new biotechnology medicines being developed; Overview on the efforts of various industry players in catching up with the research trend for such industry...

  • Innate Receives Another Milestone.  // BioWorld International;2/18/2009, Vol. 14 Issue 7, p5 

    The article reports on another milestone received by Innate Pharma SAS from the Danish pharmaceutical company Novo Nordisk A/S under their collaboration for the development of monoclonal antibodies for the treatment of chronic inflammatory conditions and autoimmune diseases. The milestone marks...

  • Genmab Lands $1.1B Cancer Deal with 'Perfect Partner' J&J. Moran, Nuala // BioWorld International;9/5/2012, Vol. 17 Issue 36, p1 

    This article reports on the partnership formed by Genmab A/S with Janssen Biotech Inc. for its anti-CD38 monoclonal antibody daratumumab. The deal is valued at more than 1.1 billion U.S. dollars and involves a worldwide commercialization of the product. The product is currently in two Phase I/II...

  • Medlmmune: collaboration with Trellis strengthens RSV pipeline.  // PharmaWatch: Monthly Review;Jan2010, Vol. 9 Issue 1, p23 

    In this article the author discusses the decision of MedImmune Inc. to license the rights of Trellis Bioscience Inc. to develop its monoclonal antibody products for treating respiratory syncytial virus (RSV). The author stresses that the company has already one RSV product on the market and has...

  • MAGIC BULLETS WITH A HEFTY PRICE TAG. Shaughnessy, Allen // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p18 

    The article discusses the sale and use of monoclonal antibodies such as Alemtuzumab and Natalizumab and their marketing by drug manufacturing companies. It explains the use of monoclonal antibodies for treatment and the evidence supporting it. It states the reason for expensiveness of monoclonal...

  • Winning strategies for effective collaboration in the pharmaceutical industry. Rowlands, Charles; Morgan, Amy; Hawksworth, Gary // Journal of Medical Marketing;Mar2006, Vol. 6 Issue 2, p83 

    This paper examines key success factors for effective collaboration in the pharmaceutical industry. In an industry where speed to market is critical and where informed and timely decisions can have large financial implications, collaboration is a key factor to ensure value is delivered....

  • IPT, Meristem and Croptech Race Toward the MAb Market. Jarvis, Lisa // Chemical Market Reporter;9/24/2001, Vol. 260 Issue 11, p10 

    Reports on the research conducted by pharmaceutical companies on the application of transgenic corn in the production of human monoclonal antibodies. Problems faced in the development of monoclonal antibodies; Significance of the success of biotechnology-based drugs; Competition between...

  • U.S. Faces Protein Deficiency. Creswell, Julie // Fortune;5/28/2001, Vol. 143 Issue 11, p30 

    Focuses on the development of protein drugs which include monoclonal antibodies called mabs. How the drugs are based on human proteins and have fewer side effects that traditional therapies; Difficulty of making the drugs, which are created chiefly from the cells of Chinese hamster ovaries or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics